Schering ends Melacine comarketing agreement
Executive Summary
Corixa is looking for comarketing partner for melanoma vaccine Melacine after Schering-Plough bows out of their sales and marketing agreement July 31. Schering's decision comes five months after an FDA Oncologic Drugs Advisory Committee recommended that Melacine undergo a second Phase III trial with relapse free survival as a primary endpoint (1"The Pink Sheet" March 4, p 31)...